Molecular Profiles Introduces New Nanoscale Predictive Analytical Screening Solution for APIs

Released on: February 26, 2008, 5:41 am

Press Release Author: Molecular Profiles Ltd

Industry: Pharmaceuticals

Press Release Summary: Molecular Profiles, a global leader in the provision of
innovative contract research services to the pharmaceutical, biopharmaceutical and
biomedical sectors, announces the latest addition to its comprehensive nanoscale
analytical services offering, nanoPASSTM (nanoscale Predictive Analytical Screening
Solution). This innovative new service platform is a comprehensive suite of
complementary analytical techniques designed to optimise solid state selection of
APIs and provide further insight into the formulation of APIs and excipients.

Press Release Body: Molecular Profiles, a global leader in the provision of
innovative contract research services to the pharmaceutical, biopharmaceutical and
biomedical sectors, announces the latest addition to its comprehensive nanoscale
analytical services offering, nanoPASSTM (nanoscale Predictive Analytical Screening
Solution). This innovative new service platform is a comprehensive suite of
complementary analytical techniques designed to optimise solid state selection of
APIs and provide further insight into the formulation of APIs and excipients.

Processing of drug substance and excipients can have a significant effect on surface
properties and subsequent stability/bioavailability of the active. To decide on the
best formulation option, full understanding of bulk and surface physicochemical
properties is required. Enabling technologies allow empirical observations such as
batch-to-batch variation, cohesive tendency and powder flow to be correlated to
actual physicochemical properties.

The nanoPASSTM suite has been equipped with an extended range of analytical
techniques, including nanoscale determination of materials, mechanical and cohesive
properties, chemical spectroscopy, physical properties (XRPD and thermal
techniques), high-resolution spatial mapping and imaging of chemical, physical,
thermal and material properties. The unique solid state characterisation
capabilities of the service platform enable users to compare bulk and surface
properties of drug substance, excipients, granules and aggregates providing them
with a detailed physicochemical profile.

The nanoPASSTM service platform requires only small amounts of sample to provide
precise and dependable material characterisation. An example of the power of the
analytical benefits afforded by nanoPASSTM is the pre-formulation screening of the
physical properties of single formulated particles using Atomic Force Microscopy
(AFM), which provides deep insight into the pharmaceutical function of developmental
products.

"The introduction of this novel service platform further demonstrates our dedication
to providing a high quality and reliable extension to the R&D capabilities within
pharmaceutical companies," comments Dr. Nikin Patel, CEO, Molecular Profiles. "Our
team of specialised, experienced scientists will be building upon this platform to
develop an extended range of service offerings intended to provide our customers
with even more clarity and choice."


Web Site: http://www.molprofiles.co.uk

Contact Details: More information about nanoPASSTM and Molecular Profiles'
award-winning contract research services is available at www.molprofiles.co.uk, by
e-mail at enquiry@molprofiles.co.uk, alternatively, call Dr. Nikin Patel on +44 115
8718888.

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •